Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series

BACKGROUND: Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Zhou, Rui, Cheng, Xianzhong, Xu, Xia, Guo, Wenwen, Chen, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079537/
https://www.ncbi.nlm.nih.gov/pubmed/32183851
http://dx.doi.org/10.1186/s13048-020-00629-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079537/
https://www.ncbi.nlm.nih.gov/pubmed/32183851
http://dx.doi.org/10.1186/s13048-020-00629-4

Ejemplares similares